엑소좀 기반 치료제 시장 규모, 점유율 및 동향 분석 보고서 : 제품 유형별, 유래별, 치료 용도별, 최종사용자별, 지역별 및 부문별 예측(2026-2033년)

Exosome-based Therapeutics Market Summary

The global exosome-based therapeutics market size was valued at USD 56.28 million in 2025, is anticipated to grow from USD 66.48 million in 2026 to reach USD 220.20 million by 2033, growing at a CAGR of 18.66% from 2026 to 2033. North America exosome-based therapeutics market held the largest share of 39.41% of the global market in 2025.

The exosome-based therapeutics market is emerging as a next-generation segment within advanced biologics and regenerative medicine, driven by the increasing exploration of extracellular vesicles (EVs) as natural carriers for intercellular communication and targeted drug delivery. Exosomes are gaining attention due to their ability to transport proteins, lipids, and nucleic acids with high biocompatibility and low immunogenicity, making them attractive candidates for precision medicine applications. The market is being shaped by growing research into engineered exosomes for therapeutic delivery, particularly in oncology, neurology, and inflammatory disorders. Increasing interest from biotechnology companies and academic institutions is accelerating translational research, while advancements in isolation, purification, and characterization technologies are improving scalability and clinical feasibility. However, the field is still in an early developmental stage, with most candidates in preclinical or early clinical phases.

The market is further supported by expanding applications in regenerative medicine and cell-free therapies, where exosomes are being investigated for tissue repair, immune modulation, and anti-inflammatory effects. Their ability to mimic the functional properties of stem cells without the risks associated with live-cell transplantation is strengthening their clinical appeal. Key research areas include neurological disorders such as Alzheimer's disease, Parkinson's disease, and spinal cord injuries, where exosomes are being evaluated for their potential to cross biological barriers and deliver therapeutic payloads to the central nervous system. In oncology, exosome platforms are being explored for both drug delivery and biomarker-based diagnostics, enabling earlier disease detection and personalized treatment approaches. Despite strong scientific momentum, challenges such as large-scale manufacturing, standardization of isolation techniques, and regulatory uncertainty continue to limit widespread commercialization.

Increasing investments, strategic collaborations, and rising participation from biotechnology companies are accelerating the transition of exosome-based therapeutics from research to clinical validation. Companies are actively focusing on engineered exosome platforms, scalable production technologies, and advanced cargo-loading methods to enhance therapeutic efficiency and reproducibility. The competitive landscape remains highly fragmented, with multiple early-stage players and limited commercial products currently available. North America dominates research activity due to strong academic-industry collaboration and funding support, while Europe and Asia Pacific are witnessing increasing participation in clinical development initiatives. Overall, the exosome-based therapeutics market is expected to evolve gradually, with long-term growth potential driven by advancements in bioengineering, regulatory clarity, and successful clinical translation of lead candidates.

Global Exosome-based Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global exosome-based therapeutics market report based on product type, source, therapeutic application, end user, and region:

• Product Type Outlook (Revenue, USD Million, 2021 - 2033)
• Native Exosome Therapeutics
• Engineered Exosome Therapeutics
• Exosome-based Drug Delivery Therapeutics
• Hybrid Exosome Therapeutics
• Source Outlook (Revenue, USD Million, 2021 - 2033)
• Mesenchymal Stem Cell (MSC)-Derived Exosomes
• Immune Cell-Derived Exosomes
• Tumor Cell-Derived Exosomes
• Plasma/Biofluid-Derived Exosomes
• Other Cell Source-Derived Exosomes
• Therapeutic Application Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Neurology
• Cardiovascular Diseases
• Immunology & Inflammatory Diseases
• Dermatology & Regenerative Medicine
• Infectious Diseases
• Rare Diseases
• Other Therapeutic Applications
• End User Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biotechnology Companies
• Research & Academic Institutes
• Contract Development & Manufacturing Organizations (CDMOs/CROs)
• Hospitals & Specialty Clinics
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product Type
  • 1.2.2. Source
  • 1.2.3. Therapeutic Application
  • 1.2.4. End User
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Exosome-based Therapeutics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Exosome-based Therapeutics Market: Product Type Business Analysis

• 4.1. Product Type Market Share, 2025 & 2033
• 4.2. Product Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product Type, 2021 to 2033 (USD Million)
• 4.4. Native Exosome Therapeutics
  • 4.4.1. Native Exosome Therapeutics Market, 2021 - 2033 (USD Million)
• 4.5. Engineered Exosome Therapeutics
  • 4.5.1. Engineered Exosome Therapeutics Market, 2021 - 2033 (USD Million)
• 4.6. Exosome-based Drug Delivery Therapeutics
  • 4.6.1. Exosome-based Drug Delivery Therapeutics Market, 2021 - 2033 (USD Million)
• 4.7. Hybrid Exosome Therapeutics
  • 4.7.1. Hybrid Exosome Therapeutics Market, 2021 - 2033 (USD Million)

Chapter 5. Exosome-based Therapeutics Market: Source Business Analysis

• 5.1. Source Market Share, 2025 & 2033
• 5.2. Source Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Source, 2021 to 2033 (USD Million)
• 5.4. Mesenchymal Stem Cell (MSC)-Derived Exosomes
  • 5.4.1. Mesenchymal Stem Cell (MSC)-Derived Exosomes Market, 2021 - 2033 (USD Million)
• 5.5. Immune Cell-Derived Exosomes
  • 5.5.1. Immune Cell-Derived Exosomes Market, 2021 - 2033 (USD Million)
• 5.6. Tumor Cell-Derived Exosomes
  • 5.6.1. Tumor Cell-Derived Exosomes Market, 2021 - 2033 (USD Million)
• 5.7. Plasma/Biofluid-Derived Exosomes
  • 5.7.1. Plasma/Biofluid-Derived Exosomes Market, 2021 - 2033 (USD Million)
• 5.8. Other Cell Source-Derived Exosomes
  • 5.8.1. Other Cell Source-Derived Exosomes Market, 2021 - 2033 (USD Million)

Chapter 6. Exosome-based Therapeutics Market: Therapeutic Application Business Analysis

• 6.1. Therapeutic Application Market Share, 2025 & 2033
• 6.2. Therapeutic Application Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Application, 2021 to 2033 (USD Million)
• 6.4. Oncology
  • 6.4.1. Oncology Market, 2021 - 2033 (USD Million)
• 6.5. Neurology
  • 6.5.1. Neurology Market, 2021 - 2033 (USD Million)
• 6.6. Cardiovascular Diseases
  • 6.6.1. Cardiovascular Diseases Market, 2021 - 2033 (USD Million)
• 6.7. Immunology & Inflammatory Diseases
  • 6.7.1. Immunology & Inflammatory Diseases Market, 2021 - 2033 (USD Million)
• 6.8. Dermatology & Regenerative Medicine
  • 6.8.1. Dermatology & Regenerative Medicine Market, 2021 - 2033 (USD Million)
• 6.9. Infectious Diseases
  • 6.9.1. Infectious Diseases Market, 2021 - 2033 (USD Million)
• 6.10. Rare Diseases
  • 6.10.1. Rare Diseases Market, 2021 - 2033 (USD Million)
• 6.11. Other Therapeutic Applications
  • 6.11.1. Other Therapeutic Applications Market, 2021 - 2033 (USD Million)

Chapter 7. Exosome-based Therapeutics Market: End User Business Analysis

• 7.1. End User Market Share, 2025 & 2033
• 7.2. End User Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by End User, 2021 to 2033 (USD Million)
• 7.4. Pharmaceutical & Biotechnology Companies
  • 7.4.1. Pharmaceutical & Biotechnology Companies Market, 2021 - 2033 (USD Million)
• 7.5. Research & Academic Institutes
  • 7.5.1. Research & Academic Institutes Market, 2021 - 2033 (USD Million)
• 7.6. Contract Development & Manufacturing Organizations (CDMOs/CROs)
  • 7.6.1. Contract Development & Manufacturing Organizations (CDMOs/CROs) Market, 2021 - 2033 (USD Million)
• 7.7. Hospitals & Specialty Clinics
  • 7.7.1. Hospitals & Specialty Clinics Market, 2021 - 2033 (USD Million)

Chapter 8. Exosome-based Therapeutics Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2025 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 8.4. North America
  • 8.4.1. North America Exosome-based Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Framework
    • 8.4.2.5. U.S. Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Framework
    • 8.4.3.5. Canada Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Framework
    • 8.4.4.5. Mexico Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Framework
    • 8.5.2.5. UK Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Framework
    • 8.5.3.5. Germany Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement Framework
    • 8.5.4.5. France Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Target Disease Prevalence
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Reimbursement Framework
    • 8.5.5.5. Italy Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Target Disease Prevalence
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Reimbursement Framework
    • 8.5.6.5. Spain Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Target Disease Prevalence
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Reimbursement Framework
    • 8.5.7.5. Denmark Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Target Disease Prevalence
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Reimbursement Framework
    • 8.5.8.5. Sweden Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Target Disease Prevalence
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Reimbursement Framework
    • 8.5.9.5. Norway Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Framework
    • 8.6.2.5. Japan Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Framework
    • 8.6.3.5. China Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Framework
    • 8.6.4.5. India Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Framework
    • 8.6.5.5. Australia Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Target Disease Prevalence
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Reimbursement Framework
    • 8.6.6.5. South Korea Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Target Disease Prevalence
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Reimbursement Framework
    • 8.6.7.5. Thailand Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Target Disease Prevalence
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement Framework
    • 8.7.2.5. Brazil Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Target Disease Prevalence
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement Framework
    • 8.7.3.5. Argentina Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.8. Middle East and Africa
  • 8.8.1. Middle East and Africa Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Target Disease Prevalence
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Reimbursement Framework
    • 8.8.2.5. South Africa Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Target Disease Prevalence
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Reimbursement Framework
    • 8.8.3.5. Saudi Arabia Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Target Disease Prevalence
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Reimbursement Framework
    • 8.8.4.5. UAE Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Target Disease Prevalence
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Reimbursement Framework
    • 8.8.5.5. Kuwait Exosome-based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Codiak BioSciences
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Evox Therapeutics
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Capricor Therapeutics
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Aegle Therapeutics
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Exopharm
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. ExoCoBio
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Kimera Labs
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. Aruna Bio
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Direct Biologics
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. ReNeuron Group plc
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives